Drug Profile

KLM 465

Alternative Names: KLM-465

Latest Information Update: 27 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Jul 2022 Discontinued - Phase-II for Blood dyscrasias in Switzerland (unspecified route)
16 Mar 2018 Ligand Pharmaceuticals and Novartis enter into a licensing agreement for KLM 465 (Ligand Pharmaceuticals pipeline, March 2018)
16 Mar 2018 Phase-II clinical trials in Blood dyscrasias in Switzerland (Ligand Pharmaceuticals pipeline, March 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com